Omalizumab for urticaria | DermNet
Omalizumab is a humanised monoclonal antibody ( biological treatment) that binds to circulating immunoglobulin E ( IgE) and reduces the release of inflammatory mediators from mast cells and basophils. In New Zealand, it is currently (as of 2020) licensed as an add-on therapy for patients with severe, persistent allergic asthma and for patients ...